This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Tralokinumab for adolescents with moderate to severe atopic dermatitis

< Back

Tralokinumab for adolescents with moderate to severe atopic dermatitis


Skin Disease, Burns and Wound Care

May 2020

Tralokinumab is proposed for the treatment of moderate to severe atopic dermatitis (AD) in adolescent patients (12-17 years old). AD is a chronic inflammatory skin disease that affects both children and adults and is characterised by redness, itchiness, and scaling of the skin. Some people only have small patches of dry skin, but others may experience widespread red, inflamed skin all over the body. Patients with moderate to severe AD could experience sleep disturbances, anxiety, depression, and poor quality of life. Currently, the management of AD involves the removal or treatment of trigger factors that contribute to the development of the disease.

Tralokinumab is a human monoclonal antibody that binds and neutralises the effect of the protein, interleukin 13 (IL-13), which plays a key role in triggering immune system responses in patients leading to AD. Tralokinumab is administered subcutaneously and is currently licenced for the treatment of adults. Evidence from clinical trials suggests an improvement in disease symptoms. If licensed, tralokinumab will offer an additional treatment option for adolescents with moderate to severe AD.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article


Connect to the Innovation Observatory


Load More Related Posts

Get Alerts